Stats, you might want to take a look at the cash situation at Pfizer.  A substantial amount of their earnings comes from non-US sources so a substantial amount of their cash sits in . . . . non-US places.  Which means it would cost them to get it back to the US.  If they must repatriate cash to maintain their dividend to US shareholders, that dividend starts to get more expensive in a hurry.

By the way, what did you do with BAC?  I've read in various places (including from the Morningstar analyst who is the wife of Josh) that there's a 50-80% chance they will have to raise capital or cut the dividend - or both - if the Countrywide deal goes forward.

I still hold some PFE at a relatively low price but got out of BAC a month or so ago when it was at $39 and change.

Regards.

Cliff